+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Crohn's Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Crohn's Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Crohn's Disease Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6014389
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Crohn’s Disease Therapeutics Market is experiencing a period of sustained evolution, driven by clinical innovation, new treatment modalities, and shifting payer and regulatory landscapes. Senior decision-makers must navigate this complex environment with strategies attuned to both opportunity and risk.

Market Snapshot: Crohn’s Disease Therapeutics Market Growth & Dynamics

The Crohn’s Disease Therapeutics Market grew from USD 14.00 billion in 2025 to USD 14.68 billion in 2026 and is forecast to expand at a CAGR of 5.90%, reaching USD 20.92 billion by 2032. Market momentum is fueled by advances in biologics, the introduction of targeted small-molecule therapies, and increased focus on patient-centric care delivery, all underpinned by evolving regulatory standards and payer requirements.

Scope & Segmentation

This comprehensive report provides an in-depth analysis of therapeutic approaches, business models, and regional trends shaping strategic decisions:

  • Therapy Classes: Biologics, Immunosuppressants, and Small Molecules are fully profiled. Biologics are further segmented into Integrin Inhibitors, Interleukin Inhibitors, and TNF Inhibitors, with product-level examples enhancing decision relevance.
  • Route of Administration: Intravenous, oral, and subcutaneous options are compared for their roles in patient adherence, care setting flexibility, and operational efficiency.
  • Distribution Channels: Analysis covers hospital pharmacies, retail pharmacies, and specialty clinics, highlighting distinct reimbursement and service requirements across channels.
  • End User Settings: Insights are tailored to hospitals, home care, and specialty clinics, with focus on the balance between institutional throughput and patient self-management needs.
  • Region Coverage: The Americas, Europe Middle East & Africa, and Asia-Pacific are evaluated through the lens of regulatory diversity, commercial access models, and infrastructure maturity to inform go-to-market planning.
  • Technology Trends: The report examines digital health’s impact, particularly remote monitoring, adherence solutions, and the adoption of real-world evidence as part of therapy differentiation.

Key Takeaways for Industry Leaders

  • Innovation in therapeutic classes, including biologics and small molecules, is producing differentiated mechanisms and enabling more personalized Crohn’s disease management.
  • Payer scrutiny is refocusing commercialization strategies towards therapies that demonstrate clear clinical benefit, long-term safety, and cost-effectiveness across diverse patient populations.
  • Operational considerations—such as route of administration and distribution channel—now play a central role in delivering patient value and managing total cost of care.
  • Effective competitive and collaborative strategies, including co-development, licensing, and selective partnerships, are essential for advancing clinical programs and accessing scalable manufacturing.
  • Regional differences in adoption drivers, health technology assessments, and procurement models require adaptive access strategies that balance global ambitions with local market realities.
  • Companies investing in real-world evidence platforms and patient support services gain a performance advantage by improving both payer engagement and therapy adherence.

Tariff Impact: 2025 U.S. Policy Shifts

Recent U.S. tariff changes have influenced pharmaceutical supply chains and pricing structures for Crohn’s disease therapeutics. Manufacturers are re-evaluating sourcing strategies and pursuing supplier diversification and localized manufacturing to withstand cost fluctuations and maintain access. Contracting negotiations and value-based arrangements are intensifying as providers and payers respond to shifting cost burdens. These changes necessitate careful resilience planning, especially for organizations with international supply relationships or limited scale.

Methodology & Data Sources

Findings are backed by structured interviews with clinical experts, market access professionals, and commercial leaders, augmented by systematic reviews of peer-reviewed literature, regulatory filings, and policy documents. Cross-validation with analytic models and secondary data ensures reliability, while segmentation mapping aligns clinical, commercial, and operational factors. Quality assurance steps include peer review and sensitivity analysis.

Why This Report Matters

  • Enables R&D, commercial, and access strategists to identify high-impact investment opportunities across therapy classes, care settings, and regional markets.
  • Equips executives with actionable insights to mitigate commercial, operational, and regulatory risks while driving sustained market growth.
  • Supports competitive positioning through evidence-based understanding of market segmentation, technological trends, and payer behavior.

Conclusion

The Crohn’s disease therapeutics market is shaped by active differentiation, regional diversity, and increased demand for patient-centered outcomes. Success relies on integrating innovation, resilient supply strategies, and adaptive access approaches to achieve sustainable growth and improved patient benefit.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Crohn's Disease Therapeutics Market, by Therapy Class
8.1. Biologics
8.1.1. Integrin Inhibitors
8.1.2. Interleukin Inhibitors
8.1.2.1. Risankizumab
8.1.2.2. Ustekinumab
8.1.3. TNF Inhibitors
8.1.3.1. Adalimumab
8.1.3.2. Certolizumab
8.1.3.3. Infliximab
8.2. Immunosuppressants
8.2.1. Methotrexate
8.2.2. Thiopurines
8.2.2.1. Azathioprine
8.2.2.2. Mercaptopurine
8.3. Small Molecules
9. Crohn's Disease Therapeutics Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Crohn's Disease Therapeutics Market, by Distribution Channel
10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Specialty Clinics
11. Crohn's Disease Therapeutics Market, by End User
11.1. Home Care Settings
11.2. Hospitals
11.3. Specialty Clinics
12. Crohn's Disease Therapeutics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Crohn's Disease Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Crohn's Disease Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Crohn's Disease Therapeutics Market
16. China Crohn's Disease Therapeutics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. Amgen Inc.
17.7. Arena Pharmaceuticals, Inc.
17.8. AstraZeneca plc
17.9. Bayer AG
17.10. Biogen Inc.
17.11. Boehringer Ingelheim International GmbH
17.12. Bristol Myers Squibb Company
17.13. Celgene Corporation
17.14. Eli Lilly and Company
17.15. Galapagos NV
17.16. Gilead Sciences, Inc.
17.17. GlaxoSmithKline plc
17.18. Janssen Pharmaceuticals, Inc.
17.19. Johnson & Johnson Services, Inc.
17.20. Merck & Co., Inc.
17.21. MorphoSys AG
17.22. Novartis AG
17.23. Pfizer Inc.
17.24. Roche Holding AG
17.25. Sanofi S.A.
17.26. Takeda Pharmaceutical Company Limited
17.27. Theravance Biopharma, Inc.
17.28. UCB S.A.
17.29. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 126. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 127. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 128. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 129. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 130. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 131. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 146. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 147. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 148. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 149. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 150. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 151. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 167. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 168. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 169. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 170. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 171. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 172. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 177. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 178. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 179. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 180. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 181. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 182. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 197. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 198. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 199. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 200. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 201. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 202. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 207. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 208. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 209. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 210. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 211. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 212. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 216. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 217. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 218. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 219. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 220. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 221. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 222. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 238. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 239. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
TABLE 240. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 241. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 242. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
TABLE 243. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Crohn's Disease Therapeutics market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • MorphoSys AG
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma, Inc.
  • UCB S.A.
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages183
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 14.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 20.92 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Crohn's Disease Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Crohn's Disease Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Anti-Inflammatory Therapeutics Market - Global Forecast 2026-2032 - Product Image

Anti-Inflammatory Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Autoimmune Disease Drugs Market - Global Forecast 2026-2032 - Product Image

Autoimmune Disease Drugs Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Crohn's Disease Therapeutics Market - Product Image

Crohn's Disease Therapeutics Market

  • Report
  • 150 Pages
  • Global
From

About the Crohn Disease Drug Market

Crohn Disease is a chronic inflammatory disorder of the gastrointestinal tract, and is one of the most common immune disorders. Treatment for Crohn Disease typically involves a combination of medications, lifestyle changes, and in some cases, surgery. Common medications used to treat Crohn Disease include corticosteroids, immunomodulators, biologic therapies, and antibiotics. Corticosteroids are used to reduce inflammation, while immunomodulators are used to suppress the immune system. Biologic therapies are used to target specific proteins in the body that are involved in the inflammatory process, and antibiotics are used to treat bacterial infections. The Crohn Disease Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of Crohn Disease, as well as the development of new and innovative treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.